TheraVet Retains a Leading US Veterinary Consulting Firm to Help Strategize Company Growth on the US Market
20 Febbraio 2024 - 7:30AM
Business Wire
- Retaining of a leading consulting firm with a solid track
record of upscaling vet companies on the US market
- To rapidly expand TheraVet presence and be recognized as a
major player in the US orthopedics market
- To assess possibilities to gain critical market size through
potential merger and acquisition options for TheraVet
Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets,
announces the recruitment of Brakke Consulting to help
strategize Company growth on the US market. Brakke –
www.brakkeconsulting.com - is one of the leading consulting firms
in the veterinary market with a solid track record of upscaling vet
companies on the US market.
TheraVet has been commercializing BIOCERA-VET® for almost a year
now in the US market, the largest market in animal health. Since
its US market entry, the Company has been focused on launching the
9 presentations of its BIOCERA-VET® line; BIOCERA-VET® COMBO-CLEAN
being the latest one launched in October 2023. To that aim, the
Company has initiated a two-pilar plan: (i) the process,
development, and delivery of direct sales to customers and (ii) the
development of the company network and products awareness with
participation in conferences, talks, clinical studies and reach to
Key Opinion Leaders.
The Company’s next objectives are to rapidly grow from its
existing base, expand its presence and to be recognized as a major
player in the US orthopedics market. TheraVet has retained
Brakke Consulting to help meet its objective based on a 3-step plan
(structured with go/no go decision points):
- In the first phase, market opportunity in the United States for
the TheraVet veterinary product line will be re-assessed. To
objectively measure this potential, a panel of vet surgeons
specialized in osteosarcoma management and orthopedics from
independent and corporate practices will be surveyed.
- Second, a new strategic and marketing plan will be
developed, proposing the best go-to-market, organizational and
partnership structure for the TheraVet veterinary business. This
phase will include assessment and modelling of the
go-to-market/organizational options and the recommendations for
TheraVet to achieve its objectives for the successful
implementation of the business plan.
- Finally, TheraVet activities will be scaled up. To create
critical size, potential merger and acquisition options,
inclusive of companies that may find TheraVet a meaningful partner
will be proposed.
This plan will be designed and implemented with the assistance
of Brakke Consulting, the premier consulting firm serving the
animal health, animal nutrition and veterinary industries on the US
market. Its consultants are seasoned industry professionals with
strong credentials in leadership, management, finance, sales,
distribution, marketing, brand development, communications, and
market research.
About TheraVet SA TheraVet is a veterinary biotechnology
company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective
treatments to improve the quality of life of pets suffering from
joint and bone diseases. For pet owners, the health of their pets
is a major concern and TheraVet’s mission is to address the need
for innovative and curative treatments. TheraVet works closely with
international opinion leaders in order to provide a more effective
response to ever-growing needs in the field of veterinary medicine.
TheraVet is listed on Euronext Growth® Paris and Brussels, has its
head office in Belgium (Gosselies) with a US subsidiary.
Webshop and more information at bioceravet.com For more
information about the company, visit the TheraVet website Follow us
on LinkedIn / Facebook / Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240219012268/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@newcap.fr Tel: + 32 (0) 489 57 76 52
Grafico Azioni TheraVet (EU:ALVET)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni TheraVet (EU:ALVET)
Storico
Da Apr 2023 a Apr 2024
